Company Profile:

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Recent News:

The Company will host a conference call and live audio webcast on Wednesday, February 27, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

The company provided full-year 2019 guidance for Xtampza ER revenues, Nucynta Franchise revenues, and total operating expenses. Xtampza ER revenue for 2019 is estimated to be between $95 million and $105 million.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

COLL’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator. The MACD is trying to cross back up. The RSI stands at 45.47 with positive bias. We rate Collegium Pharmaceutical Inc. (COLL) a STRONG BUY.